Drug Profile
Research programme: stem cell therapies - Cellaion
Alternative Names: H2StemLatest Information Update: 17 Feb 2022
Price :
$50
*
At a glance
- Originator Promethera Biosciences
- Developer Cellaion
- Class Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Alpha 1-antitrypsin deficiency
- No development reported Fibrosis; Non-alcoholic steatohepatitis
Most Recent Events
- 28 Nov 2020 No recent reports of development identified for research development in Fibrosis in Belgium
- 28 Nov 2020 No recent reports of development identified for research development in Non-alcoholic-steatohepatitis in Belgium
- 05 Oct 2017 Promethera Biosciences and Shibuya enter into collaboration to develop manufacturing platform for stem cell therapies for treatment of liver disorders